Every 10-Q that Idexx Laboratories Inc (IDXX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IDXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXX filings page.
IDEXX Laboratories, Inc. reported Q2 2026 total revenue of $1,216,585 (in thousands), up from $1,109,457, with net income of $338,412 and diluted EPS of $4.27, both higher than a year earlier. For the first six months, revenue reached $2,357,405 (in thousands) and net income $616,858.
Growth was led by the Companion Animal Group, with Q2 segment revenue of $1,118,236 (in thousands); Water and LPD also increased. Operating cash flow for the six months rose to $613,410 (in thousands), funding $703,732 (in thousands) of share repurchases while cash increased to $196,933 (in thousands).
The balance sheet shows total assets of $3,442,335 (in thousands) and borrowings of $519,000 (in thousands) under a $1.25 billion Credit Facility, with covenant compliance and $729.2 million of remaining availability. Customer commitment arrangements support estimated future revenues of approximately $5.3 billion over several years.
IDEXX Laboratories reported solid growth for the quarter ended March 31, 2026. Total revenue rose to $1.14 billion from $998.4 million a year earlier, driven mainly by higher Companion Animal Group diagnostic and software revenues and broader international demand.
Net income increased to $278.4 million from $242.7 million, with diluted earnings per share up to $3.47 from $2.96. Operating cash flow was strong at $266.2 million, supporting continued investment and capital returns, including $360.8 million of open-market share repurchases and ongoing use of the company’s credit facility and senior notes.
IDEXX Laboratories reported higher third‑quarter results in its Form 10‑Q for the period ended September 30, 2025. Total revenue rose to $1,105,239 thousand from $975,543 thousand a year ago, driven by the Companion Animal Group, where CAG Diagnostics recurring revenue reached $873,273 thousand. Product revenue was $656,159 thousand and service revenue was $449,080 thousand.
Gross profit increased to $683,354 thousand from $596,038 thousand. Net income grew to $274,610 thousand, with diluted EPS of $3.40 compared with $2.80 last year. By category within CAG, IDEXX VetLab consumables were $387,813 thousand, reference laboratory services $362,725 thousand, and CAG Diagnostics capital instruments $51,479 thousand. Water revenue was $54,297 thousand and LPD revenue was $33,944 thousand.
Year‑to‑date operating cash flow was strong at $826,045 thousand. The company repurchased $979,190 thousand of common stock year‑to‑date and ended with cash and cash equivalents of $208,166 thousand. Borrowings under the Credit Facility totaled $455,000 thousand, and total debt (current and long‑term) was $524,822 thousand as of quarter‑end. Shares outstanding were 79,851,330 on October 29, 2025.